Drug intelligence / Profile preview

AD-2081

Development stage: Unknown
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

AD-2081 is a small molecule drug developed by Addpharma for the treatment of androgenetic alopecia, a common form of hair loss in men. The drug has reached Phase 3 clinical trials, with studies conducted to evaluate its efficacy and safety in male patients with this condition. The precise mechanism of action for AD-2081 remains unknown at this time. There are no approved indications or known adverse events reported as of the latest updates. The primary route of administration is oral[1][2].

Beyond the preview

Go deeper on AD-2081.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-2081.

Explore the full profile